EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ARCA biopharma's Enterprise Value is $12.80 Mil.
ARCA biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.30 Mil. Therefore, ARCA biopharma's EV-to-EBIT for today is -1.75.
The historical rank and industry rank for ARCA biopharma's EV-to-EBIT or its related term are showing as below:
ABIO'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1.96 Med: 0 Max: 2.8
Current: -1.75
During the past 13 years, the highest EV-to-EBIT of ARCA biopharma was 2.80. The lowest was -1.96. And the median was 0.00.
ABIO's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs ABIO: -1.75
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ARCA biopharma's Enterprise Value for the quarter that ended in Dec. 2023 was $-12.58 Mil.
ARCA biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.30 Mil. ARCA biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 58.02%.
ARCA biopharma EV-to-EBIT Historical Data
The historical data trend for ARCA biopharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ARCA biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARCA biopharma EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, ARCA biopharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ARCA biopharma's EV-to-EBIT falls into.
ARCA biopharma EV-to-EBIT Calculation
ARCA biopharma's EV-to-EBIT for today is calculated as:
ARCA biopharma's current Enterprise Value is $12.80 Mil.
ARCA biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma (NAS:ABIO) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ARCA biopharma's Enterprise Value for the quarter that ended in Dec. 2023 was $-12.58 Mil.
ARCA biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of ARCA biopharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
ARCA biopharma (ARCA biopharma) Business Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABIO has been successfully added to your 